High expression of microRNA-454 is associated with poor prognosis in triple-negative breast cancer.
High expression of microRNA-454 is associated with poor prognosis in triple-negative breast cancer.
复制标题
DOI：
10.18632/oncotarget.11764
复制
发表时间：
2016-10-04
期刊：
影响因子：
--
通讯作者：
Shao ZM
中科院分区：
文献类型：
--
作者：
Cao ZG;Li JJ;Yao L;Huang YN;Liu YR;Hu X;Song CG;Shao ZM
据报道，MicroRNA-454 (miR-454) 在大多数癌症中发挥致癌或肿瘤抑制作用。然而，miR-454 在乳腺癌中的临床相关性仍不清楚。我们使用原位杂交（ISH）技术检测了包含来自复旦大学上海肿瘤中心女性患者的 534 份乳腺癌标本的组织微阵列中 miR-454 的表达。其中，250 名患者构成训练集，另外 284 名患者构成验证集。通过Kaplan-Meier方法分析miR-454与临床结果之间的关系。 miR-454 的高表达表明两个队列的无病生存 (DFS) 较差（训练集 P = 0.006；验证集 P = 0.010）。此外，在三阴性乳腺癌 (TNBC) 亚型中，miR-454 与较差的临床结果呈正相关（训练集 P = 0.013，验证集 P = 0.014）。此外，与非蒽环类化疗相比，低miR-454表达队列中的患者对蒽环类药物的反应更好（P=0.056），但在高miR-454表达队列中没有观察到这种差异。我们的研究结果表明，miR-454 是 TNBC 预后和化疗反应的潜在预测因子。
MicroRNA-454 (miR-454) has been reported to play an oncogenic or tumor suppressor role in most cancers. However, the clinical relevance of miR-454 in breast cancer remains unclear. We examined the expression of miR-454 in a tissue microarray containing 534 breast cancer specimens from female patients at Fudan University Shanghai Cancer Center using in situ hybridization (ISH). Of these, 250 patients formed the training set and the other 284 were the validation set. The relationship between miR-454 and clinical outcome was analyzed by the Kaplan-Meier method. High expression of miR-454 indicated worse disease-free survival (DFS) in both cohorts (P = 0.006 for training set; P = 0.010 for validation set). Furthermore, in the triple-negative breast cancer (TNBC) subtype, miR-454 was positively correlated with worse clinical outcome (P = 0.013 for training set, P = 0.014 for validation set). In addition, patients in the low miR-454 expression cohort had better response to anthracycline compared to non-anthracycline chemotherapy (P = 0.056), but this difference was not observed in the high miR-454 expression cohort. Our findings indicated that miR-454 is a potential predictor of prognosis and chemotherapy response in TNBC.